Cells move en masse towards rigid tissues
A new phenomenon, collective durotaxis, opens new avenues to control tumor growth and improve wound healing
The groups of Pau Gorostiza, ICREA Research Professor at IBEC, and Amadeu Llebaria of IQAC-CSIC have developed molecules that can be applied as light-regulated molecular prostheses to help restore vision in cases of retinal degeneration.
Together with their collaborators at ICIQ, INA, IRB Barcelona, CIBER-BBN and the Miguel Hernández and Alcalá de Henares universities, the researchers reveal in Nature Communications today their development of a new class of light-regulated drug, targeted covalent photoswitches (TCPs), that act as prosthetic molecules that can restore photoresponses in degenerated retinas.
The researchers have found a way to reduce the natural clumping that occurs when mycobacteria cells, which possess a high content of lipids in their walls, are introduced to the usual aqueous solutions that are used for intravesical instillation in bladder cancer patients. This clumping may interfere with the interaction of the mycobacteria-host cells and negatively influence their antitumor effects.
IBEC recently became home to the first 3D bioprinter in Catalonia, which promises to open up exciting new avenues in tissue and organ regeneration. First, though, in a collaboration with the UPF, the CINVESTAV-Monterrey in Mexico, and the University of Washington, the Barcelona-based scientists developed a new way of producing microfluidic devices – systems in which low volumes of fluids are processed.
Manipulating protein expression to monitor cell behavior is a powerful tool in the field of biology.
The collaborators, working in Spain and the USA, describe in the journal Biomaterials how they decellularized human hearts, all of which had been determined not suitable for transplantation by the Spanish National Transplant Organization. They left the extracellular matrix, the structure that provides cells with structural and biochemical support, intact.
Until now, heparin – which has been shown to have antimalarial activity and specific binding affinity for red blood cells infected with the Plasmodium malaria parasite – has not been explored for anti-malarial drug solutions due to its powerful anticoagulating activity. While heparin is able to block the cell adhesion of infected red blood cells to various host receptors and disrupt the growth of the pathogen, its downfall is that the quantities needed for malaria treatment would result in too much blood-thinning and bleeding. There’s also the potential risk of infection, since polysaccharides such as heparin tend to be obtained from mammals.
Most E. coli bacterial strains occur naturally in the human gut and pose no harm to health, except for particular serotypes that always hit the news because they cause food poisoning that can become life threatening in certain patients. One such serotype is O104:H4, that caused a large outbreak with a high prevalence of associated hemolytic–uremic syndrome (HUS) in Germany in 2011, a newly emerged strain that caused the highest frequency of HUS and death from E. coli ever recorded.
When P. aeruginosa bacteria cause chronic lung infections in patients with cystic fibrosis or chronic obstructive pulmonary disease (COPD), it means they have been able to form a mature biofilm in situ that lets them grow and adapt. This biofilm not only enhances cell-to-cell communication for the bacteria, thus allowing the infection to increase and thrive, but it also increases the chances of developing new antibiotic resistance and escape from the body’s immune system.
The scientists and their collaborators at the Georgia Institute of Technology, publishing in and on the cover of Nature Cell Biology, have identified the mechanism by which tissue stiffness activates a protein called YAP, a major oncogene. This discovery is the result of many years’ work spent studying the forces that cells apply to their surrounding tissue – forces which determine how cells proliferate, differentiate, and move, which in turn sheds light on how development, tumorigenesis or wound healing are regulated. The discovery belongs to a family of patents in place.